

14 January 2025

## Osteopore Implants Added to Singapore's Ministry of Health's Subsidy List

### Highlights

- Osteopore's craniomaxillofacial and oculoplastic implants are now listed in Singapore's Ministry of Health (MOH) Implant Subsidy List (ISL).
- The ISL aims to encourage the use of clinically effective and cost-effective implants to improve patient outcomes and healthcare resource utilisation.
- Osteopore's continues to work on improving access to its implants.

Australian-Singaporean regenerative medicine company **Osteopore Limited (ASX: OSX; Osteopore or the Company)** – a global leader in 3D-printed biomimetic and bioresorbable implants – is pleased to announce that its craniomaxillofacial and oculoplastic implants have been added to the Implant Subsidy List (ISL) by Singapore's Ministry of Health.

The ISL comprises implants assessed to be safe, clinically and cost-effective. Subsidies are extended to implants listed on the ISL, to encourage the use of these implants to improve patient outcomes and healthcare resource utilisation.

Osteopore's craniomaxillofacial and oculoplastic implants, developed with advanced 3D-printing technology, are specifically designed to support natural tissue regeneration. Made from biodegradable polycaprolactone (PCL), these implants gradually resorb into the body over 18-24 months, providing structural support as they promote bone healing.

The inclusion of Osteopore's implants on the ISL enables patients in public healthcare facilities to access these advanced solutions at a subsidised cost, making regenerative treatments more affordable for eligible patients. This development expands opportunities for patients to benefit from Osteopore's cutting-edge technology, which promotes faster recoveries and reduces the risk of complications. Incorporating these implants into the ISL represents a significant step forward in enhancing patient care and optimising healthcare resources in the public sector.

Osteopore remains committed to advancing healthcare solutions that are both effective and affordable.

On 16 May 2023, Osteopore announced that it has received reimbursement approval from Discovery Health Medical Scheme (DHMS), the largest South African Medical Insurer. Along with this inclusion to the ISL by the Singapore's Ministry of Health, Osteopore has demonstrated its resolve to provide easier access to its implants.

**Commenting on Osteopore's Inclusion in the ISL, Osteopore CEO, Dr. Yujing Lim, said:**

"The inclusion of our implants to the Implant Subsidy List is a meaningful recognition of Osteopore's commitment to providing innovative, patient-centred solutions. This step by the Ministry of Health enables us to provide more patients with access to affordable, advanced regenerative treatments that facilitate natural recovery processes. We are pleased to contribute to Singapore's healthcare landscape and look forward to continuing our efforts in delivering impactful solutions that improve patient outcomes and enhance quality of life," said Dr Lim.

In *The Future of Medtech in Australia*, RSM highlighted Osteopore's 'bright future as a regenerative medicine leader'. Osteopore is committed to broadening its collaboration with leading-edge businesses and expanding its presence in nascent markets to continue pushing the boundaries of regenerative medicine.

This announcement dated 14 January 2025 has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

**Dr Yujing Lim**

Chief Executive Officer

Osteopore Limited

E: [lim\\_yujing@osteopore.com](mailto:lim_yujing@osteopore.com)**Isaac Stewart**

Media &amp; Investor Relations

Purple

E: [istewart@purple.au](mailto:istewart@purple.au)**About Osteopore Limited**

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

**About Implant Subsidy List**

Subsidies are extended to implants listed on the ISL to encourage the use of these implants that are assessed to be clinically effective and cost-effective. This improves patient outcomes and healthcare resource utilisation. Patients will be eligible for means-tested subsidies when these implants are used in public healthcare institutions in accordance with the clinical criteria for subsidy eligibility as stipulated in the ISL.

<https://www.moh.gov.sg/managing-expenses/schemes-and-subsidies/implant-subsidy-list/>

**Forward-Looking Statements**

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors,

**ASX ANNOUNCEMENT**

employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement. You are cautioned not to place undue reliance on any forward-looking statement.

The forward-looking statements in this announcement reflect views held only as of the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their advice before making any investment decision.

For personal use only

